NCT06244212 Topical Treatment for Atopic Dermatitis
| NCT ID | NCT06244212 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Wake Forest University Health Sciences |
| Condition | Atopic Dermatitis |
| Study Type | INTERVENTIONAL |
| Enrollment | 30 participants |
| Start Date | 2024-09-19 |
| Primary Completion | 2026-07 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 30 participants in total. It began in 2024-09-19 with a primary completion date of 2026-07.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Medication adherence is a poorly studied phenomenon that challenges both patients and physicians. 50% of individuals with chronic disease are not adherent to their medication regimen. Within the United States, non-adherence to medical treatment leads to approximately $100 billion in hospital admission costs. While the issue of adherence is not limited to any particular field of medicine, non-adherence occurs in approximately one-third to one-half of dermatological patients. Non-adherence is of importance as it is a significant cause of treatment failure, resulting in worse quality of life, worse health outcomes, and increased insurance costs.
Eligibility Criteria
Inclusion Criteria: * Diagnosis of skin dermatitis * Age \> 9 * Ability to return for a one-week clinical studies follow-up * Patients who are candidates for treatment with 0.1% triamcinolone ointment (even if they weren't in the study) * Adult or pediatric patients with active dermatitis who receive dermatologic care at Atrium Health Wake Forest Baptist, Department of Dermatology. Exclusion Criteria: * Patients without the diagnosis of skin dermatitis * Inability to return for a one week follow up appointment * Body Surface Area (BSA) affected \<2%
Contact & Investigator
Steven R Feldman, MD, PhD
PRINCIPAL INVESTIGATOR
Wake Forest University Health Sciences
Frequently Asked Questions
Who can join the NCT06244212 clinical trial?
This trial is open to participants of all sexes, aged 9 Years or older, studying Atopic Dermatitis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06244212 currently recruiting?
Yes, NCT06244212 is actively recruiting participants. Contact the research team at irichard@wakehealth.edu for enrollment information.
Where is the NCT06244212 trial being conducted?
This trial is being conducted at Winston-Salem, United States.
Who is sponsoring the NCT06244212 clinical trial?
NCT06244212 is sponsored by Wake Forest University Health Sciences. The principal investigator is Steven R Feldman, MD, PhD at Wake Forest University Health Sciences. The trial plans to enroll 30 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.